Fortress Biotech (NASDAQ: FBIO) — Company Overview, News & Financial Data
Fortress Biotech is a biopharmaceutical company focused on developing drugs for unmet medical needs across various diseases.
Fortress Biotech
Fortress Biotech (NASDAQ:FBIO) is a biopharmaceutical company dedicated to acquiring, developing, and commercializing high-potential marketed and development-stage drugs and drug candidates. The company is especially focused on therapies that can address unmet medical needs across a broad range of disease areas, including oncology, rare diseases, and infectious diseases. Through partnerships and subsidiary companies, Fortress Biotech advances its diversified portfolio, leveraging its expertise to strive for success across different therapeutic fields. The company's objectives revolve around transforming cutting-edge scientific research into groundbreaking treatments, aiming to improve patient outcomes and quality of life.
Snapshot
Operations
Products and/or services of Fortress Biotech
- Cosibelimab, a late-stage, potential best-in-class, anti-PD-L1 monoclonal antibody for metastatic cutaneous squamous cell carcinoma.
- MB-107 and MB-207, novel lentiviral gene therapies for X-linked severe combined immunodeficiency.
- Avenue Therapeutics, developing intravenous tramadol to manage acute pain in adults.
- Triplex, a vaccine in development aimed at preventing cytomegalovirus in stem cell transplant recipients.
- BAER-101, an early-stage gene therapy for the treatment of Krabbe disease.
Fortress Biotech executive team
- Lindsay Allan RosenwaldExecutive Chairman, President & CEO
- David JinCFO & Head of Corporate Development
- Xiaoqin LuChief Strategy Officer
- Michael S. WeissExecutive Vice Chairman of Strategic Development & Director
Latest news about Fortress Biotech
Key financials
Reported results for Fortress Biotech, in USD.
- Market cap
- 64.7M
- Revenue (TTM)
- 68.5M
- P/E ratio
- 0.7
- EPS (diluted, TTM)
- 2.8
- Dividend yield
- —
- Profit margin
- 163.3%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 63.3M | -70.2M | 6.8M | |
| 57.7M | -110.4M | -46M | |
| 84.5M | -142.3M | -60.6M | |
| 75.7M | -203.6M | -86.6M |